{"id":1036,"date":"2024-04-24T10:54:21","date_gmt":"2024-04-24T08:54:21","guid":{"rendered":"https:\/\/lensounds.com\/2024\/04\/24\/atonco-et-le-gip-arronax-signent-un-contrat-de-developpement-dun-radiopharmaceutique-innovant-pour-la-radiotherapie-alpha\/"},"modified":"2026-03-06T18:30:01","modified_gmt":"2026-03-06T17:30:01","slug":"atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy","status":"publish","type":"post","link":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/","title":{"rendered":"ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY"},"content":{"rendered":"\n<p>Atonco and <strong>GIP ARRONAX (Saint-Herblain, France)<\/strong> are joining forces to take a new step forward in the implementation of alpha-immunotherapy against cancer. Their partnership aims to develop and validate the GMP (Good Manufacturing Practice) radiopharmaceutical production process for Atonco&#8217;s <strong>ATO-101<\/strong> (Girentuximab radiolabelled with astatine-211), with a view to clinical intravesical instillation for the treatment of non-muscle-invasive bladder cancer. Through this collaboration, two key players in the Nantes radiopharmaceutical sector are combining their expertise: the development of innovative astatine-211-based radiopharmaceuticals (Atonco) and the production of radionuclides and radiopharmaceuticals for nuclear medicine research (GIP ARRONAX).<\/p>\n\n\n\n<p>This collaboration represents a key milestone in the clinical translation of astatine-211, an alpha-particle-emitting radionuclide capable of selectively destroying targeted tumor cells. It builds on the astatine-211 production expertise developed at GIP ARRONAX and follows radiochemistry research conducted in Nantes by Team 2 of CRCI2NA, which led to the development of radiolabelling and quality control methods for astatine-211-labelled Girentuximab. Within this partnership, GIP ARRONAX plays a central role in the pharmaceutical development and GMP validation of manufacturing processes and control methods, in preparation for validation batches ahead of first-in-human clinical trials.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Laurette Fisson, CMC Director and Product Development at Atonco:<\/strong> &#8220;This collaboration reinforces Atonco&#8217;s position as a leader in the development of innovative astatine-211-based radiopharmaceuticals, contributing to the advancement of targeted therapeutic options for patients with cancers resistant to standard treatments. We are delighted to work with GIP ARRONAX, a longstanding partner with recognized expertise in radiopharmaceutical research and development.&#8221;<\/p><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>F\u00e9rid Haddad, Director of GIP ARRONAX:<\/strong> &#8220;This collaboration with Atonco brings to fruition nearly 15 years of development work carried out by GIP ARRONAX on astatine-211, a promising alpha emitter. We are proud to contribute to the advancement of nuclear medicine, and particularly to the development of alpha radiotherapy, which represents a therapeutic solution of the future.&#8221;<\/p><\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">About Atonco<\/h3>\n\n\n\n<p>Atonco is a private company developing targeted radiopharmaceutical products for oncological applications. Originating from the nuclear medicine centre in Nantes, Atonco and its partners are committed to the clinical use of alpha-emitting radionuclides, particularly astatine-211.<\/p>\n\n\n\n<p>For more information, visit <a href=\"http:\/\/www.atonco-pharma.com\/\">www.atonco-pharma.com<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">About GIP ARRONAX<\/h3>\n\n\n\n<p>ARRONAX is a Public Interest Group (GIP) carrying out public interest missions in the fields of research, economic development, and training. It operates a high-energy, high-intensity multi-particle cyclotron enabling the production of non-conventional radionuclides, including astatine-211, of which it is one of only two European producers. GIP ARRONAX manufactures radiopharmaceuticals to GMP standards to support early-phase clinical research.<\/p>\n\n\n\n<p>For more information, visit <a href=\"https:\/\/www.arronax-nantes.fr\/gip-arronax\/\">https:\/\/www.arronax-nantes.fr\/gip-arronax\/<\/a><\/p>\n\n\n\n<p><a href=\"\/wp-content\/uploads\/2025\/11\/2024-04-24_ATONCO_ARRONAX_agreement.pdf\">PDF Version >><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atonco and GIP ARRONAX (Saint-Herblain, France) are joining forces to take a new step forward in the implementation of alpha-immunotherapy against cancer. Their partnership aims to develop and validate the GMP (Good Manufacturing Practice) radiopharmaceutical production process for Atonco&#8217;s ATO-101 (Girentuximab radiolabelled with astatine-211), with a view to clinical intravesical instillation for the treatment of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1037,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48],"tags":[],"class_list":["post-1036","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-atonco-press-releases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atonco &amp; GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development<\/title>\n<meta name=\"description\" content=\"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atonco &amp; GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development\" \/>\n<meta property=\"og:description\" content=\"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-24T08:54:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-06T17:30:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin27\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin27\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/\"},\"author\":{\"name\":\"admin27\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"headline\":\"ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY\",\"datePublished\":\"2024-04-24T08:54:21+00:00\",\"dateModified\":\"2026-03-06T17:30:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/\"},\"wordCount\":435,\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/arronax-800x350-1.png\",\"articleSection\":[\"Atonco press release\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/\",\"name\":\"Atonco & GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/arronax-800x350-1.png\",\"datePublished\":\"2024-04-24T08:54:21+00:00\",\"dateModified\":\"2026-03-06T17:30:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\"},\"description\":\"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/arronax-800x350-1.png\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/arronax-800x350-1.png\",\"width\":800,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/2024\\\/04\\\/24\\\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#\\\/schema\\\/person\\\/0abcc6ce783094b44c1902ff2a9283b5\",\"name\":\"admin27\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g\",\"caption\":\"admin27\"},\"sameAs\":[\"https:\\\/\\\/pulsheart-medical.com\"],\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/author\\\/admin27\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atonco & GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development","description":"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Atonco & GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development","og_description":"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.","og_url":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/","og_site_name":"Atonco","article_published_time":"2024-04-24T08:54:21+00:00","article_modified_time":"2026-03-06T17:30:01+00:00","og_image":[{"width":800,"height":350,"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png","type":"image\/png"}],"author":"admin27","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin27","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#article","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/"},"author":{"name":"admin27","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"headline":"ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY","datePublished":"2024-04-24T08:54:21+00:00","dateModified":"2026-03-06T17:30:01+00:00","mainEntityOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/"},"wordCount":435,"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png","articleSection":["Atonco press release"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/","url":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/","name":"Atonco & GIP ARRONAX Partner for ATO-101 Alpha Radiotherapy Development","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png","datePublished":"2024-04-24T08:54:21+00:00","dateModified":"2026-03-06T17:30:01+00:00","author":{"@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5"},"description":"Atonco and GIP ARRONAX collaborate on GMP radiopharmaceutical production for ATO-101 astatine-211 alpha-immunotherapy.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2024\/04\/arronax-800x350-1.png","width":800,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/2024\/04\/24\/atonco-gip-arronax-sign-development-agreement-innovative-radiopharmaceutical-alpha-radiotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"ATONCO AND GIP ARRONAX SIGN DEVELOPMENT AGREEMENT FOR AN INNOVATIVE RADIOPHARMACEUTICAL FOR ALPHA RADIOTHERAPY"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/atonco-pharma.com\/en\/#\/schema\/person\/0abcc6ce783094b44c1902ff2a9283b5","name":"admin27","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/94e7a71a0ec4632d35d5add64525ba0c3aee8df62644926cb9b386812d7ccdfb?s=96&d=mm&r=g","caption":"admin27"},"sameAs":["https:\/\/pulsheart-medical.com"],"url":"https:\/\/atonco-pharma.com\/en\/author\/admin27\/"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1036","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1036"}],"version-history":[{"count":13,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1036\/revisions"}],"predecessor-version":[{"id":1067,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/posts\/1036\/revisions\/1067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media\/1037"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/categories?post=1036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/tags?post=1036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}